Cardiovascular Systems to Webcast Fiscal 2014 Third-Quarter Earnings Conference Call Wednesday, April 30

Live Webcast at 3:45 p.m. CT (4:45 p.m. ET)

ST. PAUL, Minn.--()--Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) will host a live webcast of its fiscal 2014 third-quarter conference call on Wednesday, April 30, 2014, at 3:45 p.m. CT (4:45 p.m. ET). David Martin, president and chief executive officer, and Larry Betterley, chief financial officer, will discuss the company’s results for its fiscal third quarter ended March 31, 2014, and its financial outlook. The company will issue a post-market earnings release prior to the call on April 30.

To access the live webcast, go to the investor section of the company’s website, www.csi360.com, on the day of the conference call and click on the webcast icon. A webcast replay will be available beginning at 7:45 p.m. CT the same day.

To participate in the conference call, dial (888) 680-0890 and enter 46277045. Please dial in at least 10 minutes prior to the call. To pre-register for the call, log on to the following website: https://www.theconferencingservice.com/prereg/key.process?key=PWLJLQ4TF. When joining the call, pre-registered participants can enter their PIN code, and other participants can press *0 to reach the operator, or wait on the line for operator assistance.

If you do not have access to the Internet and want to listen to an audio replay of the conference call, dial (888) 286-8010 and enter access number 43129279. The audio replay will be available beginning at 7:45 p.m. CT on Wednesday, April 30, 2014, through 11:59 p.m. CT on Wednesday, May 7, 2014.

About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s Orbital Atherectomy Systems treat calcified plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback 360 Orbital Atherectomy System in August 2007. In October 2013, the company received FDA approval for the use of the Diamondback 360 Coronary Orbital Atherectomy System in coronary arteries. For more information, visit the company’s website at www.csi360.com.

Contacts

Cardiovascular Systems, Inc.
Jack Nielsen, 651-202-4919
j.nielsen@csi360.com
or
PadillaCRT
Matt Sullivan, 612-455-1709
matt.sullivan@padillacrt.com

Sharing

Contacts

Cardiovascular Systems, Inc.
Jack Nielsen, 651-202-4919
j.nielsen@csi360.com
or
PadillaCRT
Matt Sullivan, 612-455-1709
matt.sullivan@padillacrt.com